An ongoing clinical study involving the type 2 diabetes drug canagliflozin (Invokana) has identified a potential increased risk of lower limb amputations. The medicine used to lower blood glucose in adult patients with type 2 diabetes has shown a two-fold higher incidence of lower limb amputations, primarily of the toes in the CANagliflozin cardioVascular Assessment Study (CANVAS). ...
Potential increased risk of lower limb amputation with canaglifozin
By Nicola Garrett
16 Jun 2016